WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SYRE

Based on 1 analyst offering 12 month price targets for Spyre Therapeutics Inc

Min Forecast
$45.00+160.27%
Avg Forecast
$45.00+160.27%
Max Forecast
$45.00+160.27%

Should I buy or sell SYRE stock?

Based on 1 analyst offering ratings for Spyre Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SYRE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SYRE as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their SYRE stock forecasts and price targets.

SYRE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-08

1 of 1

Forecast return on equity

Is SYRE forecast to generate an efficient return?

Company
-33.39%
Industry
140.91%
Market
90.47%
SYRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SYRE forecast to generate an efficient return on assets?

Company
-28.28%
Industry
32.45%
SYRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SYRE earnings per share forecast

What is SYRE's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.78
Avg 2 year Forecast
-$3.03
Avg 3 year Forecast
-$2.46

SYRE revenue forecast

What is SYRE's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.0M
Avg 2 year Forecast
$1.0M

SYRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SYRE$17.29$45.00+160.27%Buy
OCS$19.02$35.33+85.77%Strong Buy
WVE$6.95$18.00+158.99%Strong Buy
NAGE$13.63$14.53+6.57%Strong Buy
ELVN$21.91$33.50+52.90%Strong Buy
View Top Biotech Stocks

Spyre Therapeutics Stock Forecast FAQ

Is Spyre Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SYRE) stock is to Buy SYRE stock.

Out of 1 analyst, 0 (0%) are recommending SYRE as a Strong Buy, 1 (100%) are recommending SYRE as a Buy, 0 (0%) are recommending SYRE as a Hold, 0 (0%) are recommending SYRE as a Sell, and 0 (0%) are recommending SYRE as a Strong Sell.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.

What is SYRE's earnings growth forecast for 2025-2027?

(NASDAQ: SYRE) Spyre Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Spyre Therapeutics's earnings in 2025 is -$208,934,000.On average, 4 Wall Street analysts forecast SYRE's earnings for 2025 to be -$167,782,900, with the lowest SYRE earnings forecast at -$215,462,213, and the highest SYRE earnings forecast at -$105,015,196. On average, 4 Wall Street analysts forecast SYRE's earnings for 2026 to be -$182,871,290, with the lowest SYRE earnings forecast at -$250,467,278, and the highest SYRE earnings forecast at -$119,500,051.

In 2027, SYRE is forecast to generate -$148,469,760 in earnings, with the lowest earnings forecast at -$148,469,760 and the highest earnings forecast at -$148,469,760.

What is SYRE's revenue growth forecast for 2027-2030?

(NASDAQ: SYRE) Spyre Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Spyre Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast SYRE's revenue for 2027 to be $60,353,561, with the lowest SYRE revenue forecast at $60,353,561, and the highest SYRE revenue forecast at $60,353,561.

In 2030, SYRE is forecast to generate $60,353,561 in revenue, with the lowest revenue forecast at $60,353,561 and the highest revenue forecast at $60,353,561.

What is SYRE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SYRE) forecast ROA is -28.28%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is SYRE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SYRE price target, the average SYRE price target is $45.00, with the highest SYRE stock price forecast at $45.00 and the lowest SYRE stock price forecast at $45.00.

The Wall Street analyst predicted that Spyre Therapeutics's share price could reach $45.00 by Apr 8, 2026. The average Spyre Therapeutics stock price prediction forecasts a potential upside of 160.27% from the current SYRE share price of $17.29.

What is SYRE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SYRE) Spyre Therapeutics's current Earnings Per Share (EPS) is -$3.04. On average, analysts forecast that SYRE's EPS will be -$2.78 for 2025, with the lowest EPS forecast at -$3.57, and the highest EPS forecast at -$1.74. On average, analysts forecast that SYRE's EPS will be -$3.03 for 2026, with the lowest EPS forecast at -$4.15, and the highest EPS forecast at -$1.98. In 2027, SYRE's EPS is forecast to hit -$2.46 (min: -$2.46, max: -$2.46).

What is SYRE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SYRE) forecast ROE is -33.39%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.